Search Results for: lung cancer

CLP recently spoke with David Hout, PhD, VP of R&D, Insight Genetics, about continuing work on the Insight ALK Screen, Insight ALK Resistance, and other biomarker-specific diagnostic tools to advance cancer care.

Researchers have now developed and tested a promising new method for screening ALK fusions in NSCLC.

The test detects all types and all stages of lung cancer, including Stage I and II.

Ronnie Andrews, Life Technologies’ president of medical sciences, has shepherded multiple acquisitions and product launches as Life continues to expand its presence in the world of clinical diagnostics. Here he looks back at 2012, and ahead to 2013.